DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.

ABSTRACT: The diagnosis of Parkinsonian disorders is currently based on clinical criteria, which have limited sensitivity until most dopaminergic neurons are lost. Here we show that cerebrospinal fluid levels of DOPA decarboxylase (DDC) (also known as aromatic L-amino acid decarboxylase) can accurately identify patients with Lewy body disease (LBD) (area under the curve (AUC) = 0.89; P_FDR = 2.6 × 10^-13) and are associated with worse cognitive performance (P < 0.05). We also found that DDC can detect preclinical LBD stages in clinically unimpaired individuals with a positive seed amplification α-synuclein assay (AUC = 0.81, P = 1.0 × 10^-5) and that this biomarker could predict progression to clinical LBD over a 3-year period in preclinical cases (hazard ratio = 3.7 pe

SUBMITTER: Pereira JB 

PROVIDER: S-EPMC10570139 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature